SLN360
silence therapeutics
['silence thera']
$sln silence therapeutics plc presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association 2022 annual meeting | marketscreener 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities